Records containing: Lassa Fever
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-08A Phase 1, Randomized, Recipient- and Observer-Blinded, Dose-Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Two Doses of Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) Administered With 3D-(6-Acyl) PHAD-SE (aPHAD-SE) Adjuvant in Healthy Adults
-
CLINICAL_TRIALS study record update · 2026-03-11A Phase 2 Study to Evaluate Safety, Tolerability, And Virologic Efficacy of ARN-75039 For the Treatment of Lassa Fever in West Africa
-
CLINICAL_TRIALS study record update · 2026-02-04Efficacy, Tolerability and Safety of New or Repurposed Drugs Against Lassa Fever in West African Countries
-
CLINICAL_TRIALS study record update · 2025-05-11A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa
-
CLINICAL_TRIALS study record update · 2025-02-06Safety and Tolerability of Adjunct Dexamethasone in Addition to Standard of Care Antiviral Therapy Compared to Standard of Care Antiviral Therapy Alone for the Treatment of Moderate to Severe Lassa Fever
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-01-29Observational Cohort Study of Lassa Fever Clinical Course and Prognostic Factors in an Epidemic Context in Nigeria
-
CLINICAL_TRIALS study record update · 2024-01-18A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath
-
CLINICAL_TRIALS study record update · 2023-02-08Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever: A Randomized Controlled Open Label Phase II Clinical Trial
-
CLINICAL_TRIALS study record update · 2022-11-21Dose-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4500 in Combination With Electroporation in Healthy Volunteers in Ghana
-
CLINICAL_TRIALS study record update · 2022-07-06Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever
-
CLINICAL_TRIALS study record update · 2021-10-13Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Lassa Fever Patients in Nigeria: a Prospective Observational Cohort Study
-
CLINICAL_TRIALS study record update · 2020-11-23Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
-
CLINICAL_TRIALS study record update · 2020-01-02Treatment of Viral Hemorrhagic Fever (Crimean-Congo Hemorrhagic Fever or Lassa Fever) With Intravenous Ribavirin in Department of Defense (DOD) Associated Medical Treatment Facilities: A Phase 2 Study